Showing results (101-110 of 133) with videos related to
Sort By:
Pageof 14
Frontiers in Oncology|May 6, 2024
Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancersNebojsa Skorupan, Cody J Peer, Xianyu Zhang, et al.Cancer Research|May 17, 2018
Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate CancerMichael A Moses, Yeong Sang Kim, Genesis M Rivera-Marquez, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 24, 2010
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancerYang-Min Ning, James L Gulley, Philip M Arlen, et al.Cancer Chemotherapy and Pharmacology|October 23, 2020
Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumorsKhanh T Do, Geraldine O'Sullivan Coyne, John L Hays, et al.Molecular Cell|February 18, 2010
Swe1Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone functionMehdi Mollapour, Shinji Tsutsumi, Alison C Donnelly, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2020
Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 TherapyMatthew D Hellmann, Pasi A Jänne, Mateusz Opyrchal, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 8, 2019
Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II StudyAnish Thomas, Rasa Vilimas, Christopher Trindade, et al.Proceedings of the National Academy of Sciences of the United States of America|July 7, 2011
Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cellsJohanny Tonos De Leon, Aki Iwai, Clementine Feau, et al.The Lancet. Oncology|January 21, 2014
Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trialArun Rajan, Corey A Carter, Arlene Berman, et al.Oncoimmunology|September 14, 2016
TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancerLauren V Wood, Antonio Fojo, Brenda D Roberson, et al.Pageof 14